Pharmacokinetics of disodium fosfomycin in broilers and dose strategies to comply with its pharmacodynamics versus Escherichia coli

Poultry Science

Volumn 89, Issue 10, 2010, Pages 2106-2115

  Gutierrez, L ^a   Ocampo, L ^a   Rosario, C ^a   Sumano, H ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Broiler; Disodium fosfomycin; Escherichia coli; Pharmacokinetics; Water medication

Indexed keywords

AVES; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 77958108355     PISSN: 00325791     EISSN: 15253171     Source Type: Journal    
DOI: 10.3382/ps.2010-00892     Document Type: Article

References (43)

1. Aramayona, J. J., M. A. Bregante, C. Solans, S. Rueda, L. J. Fraile, and M. A. Garcia. 1997. Pharmacokinetics of fosfomycin in chickens after a single intravenous dose and tissue levels following chronic oral administration. Vet. Res. 28:581-588.
2. Auckenthaler, R. 2002. Pharmacokinetics and pharmacodynamics of oralβ-lactam antibiotics as a two-dimensional approach to their efficacy. J. Antimicrob. Chemother. 50:13-17.
3. Bayrak, O. 2006. Is a single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimester of pregnancy? Int. Urogynecol. J. Pelvic Floor Dysfunct. 29:521-524.
4. Bennet, J. B., J. L. Brodie, E. J. Benner, and M. M. William. 1966. Simplified accurate method for antibiotic assay of clinical specimens. Appl. Environ. Microbiol. 14:170-177.
5. Berthelot, G., E. Bergogne-Berezin, H. Kafe, M. Daumal, and J. C. Gillon. 1983. Etude de la pénétration de la fosfomycine dans les sécrétions bronchiques. Pathol. Biol. (Paris) 31:519-521.
6. Borsa, F., A. Leroy, J. P. Fillastre, M. Godin, and B. Moultin. 1988. Comparative pharmacokinetics of trometamol-fosfomycin and calcium-fosfomycin in young and elderly adults. Antimicrob. Agents Chemother. 32:938-941.
7. Brunner, M., A. Reinprecht, U. Illievich, C. K. Spiss, K. Dietrich, M. Houte, and M. Müller. 2002. Penetration of fosfomycin into the parenchyma of human brain: A case study in three patients. Br. J. Clin. Pharmacol. 54:548-550.
8. Burnham, K. P., and D. R. Anderson. 1988. Pages 353-365 in Model Selection and Inference-A Practical Information-Theoretic Approach. Springer-Verlag, New York, NY.
9. Cho, N., M. Sekiya, I. Chin, K. Fukunaga, and K. Kunii. 1985. Fundamental and clinical studies on fosfomycin sodium in the field of obstetrics and gynecology. Jpn. J. Antibiot. 38:2045-2056.
10. Deguchi, K. 1995. Antibacterial activities of fosfomycin against recent clinical isolates from patients of otitis media and otitis externa. Jpn. J. Antibiot. 48:293-298.
11. Falagas, M. E., M. D. Kanellopoulou, D. E. Karageorgopoulos, G. Dimopoulos, P. I. Rafilidis, N. D. Skarmoutsou, and E. A. Papa-frangas. 2008. Antimicrobial susceptibility of multidrug-resistant Gram-negative bacteria to fosfomycin. Eur. J. Clin. Microbiol. 27:439-443.
12. Falagas, M. E., A. C. Kastoris, D. E. Karageorgopoulos, and P. I. Rafailidis. 2009. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: A systematic review of microbiological, animal and clinical studies. Int. J. Antimicrob. Agents 34:111-120.
13. Faragó, E., I. J. Kiss, and Z. Nábrádi. 1980. Serum and lung tissue levels of fosfomycin in humans. Int. J. Clin. Pharmacol. Ther. Toxicol. 18:554-558.
14. Ferket, P. R., and A. G. Gernat. 2006. Factors that affect feed intake of meat birds: A review. Int. J. Poult. Sci. 5:905-911.
15. Fernández, A., C. Lara, A. Loste, S. Calvo, and M. C. Marca. 2001. Control of Salmonella enteritidis phage type 4 experimental infection by fosfomycin in newly hatched chicks. Comp. Immunol. Microbiol. Infect. Dis. 24:207-216.
16. Fernández, A., C. Lara, A. Loste, and M. C. Marca. 2002. Efficacy of calcium fosfomycin for the treatment of experimental infections of broiler chickens with Escherichia coli 078:K80. Vet. Res. Commun. 26:427-436.
17. Fernández, A., C. Lara, R. Payuelo, J. Gómez, J. J. Ramos, A. Loste, M. C. Marca, and M. T. Verde. 1998. Efficacy of phos-phomycin in the control of Escherichia coli infection of broiler chickens. Res. Vet. Sci. 65:201-204.
18. Garau, J. 2008. Other antimicrobials of interest in the era of extended-spectrumβ-lactamases: Fosfomycin, nitrofurantoin and tigecycline. Clin. Microbiol. Infect. 14:198-202.
19. Goto, M., S. Masatoshi, N. Shinji, and Y. Hajime. 1981. Fosfomycin kinetics after intravenous and oral administration to human volunteers. Antimicrob. Agents Chemother. 20:393-397.
20. Gutiérrez, L., L. Ocampo, J. R. Aguilera, and H. Sumano. 2008. Pharmacokinetics of disodium-fosfomycin in mongrel dogs. Res. Vet. Sci. 85:156-161.
21. Haritova, A. M., H. A. Djeneva, L. D. Lashev, P. G. Sotirova, B. I. Gurov, and V. N. Dyankov. 2004. Pharmacokinetics of gentamicin and apramycin in turkeys, roosters, and hens in the context of pharmacokinetic-pharmacodynamic relationships. J. Vet. Pharmacol. Ther. 27:381-384.
22. Hunter, R. P., I. Mahmood, and M. N. Martinez. 2008. Prediction of xenobiotic clearance in avian species using mammalian or avian data: How accurate is the prediction? J. Vet. Pharmacol. Ther. 31:281-284.
23. Joukhadar, C., N. Klein, P. Dittrich, M. Zeitlinger, A. Geppert, K. Skhirtladze, M. Frossard, G. Heinz, and M. Müller. 2003. Target site penetration of fosfomycin in critically ill patients. J. Antimi-crob. Chemother. 51:1247-1252.
24. Kahan, F. M., J. S. Kahan, P. J. Cassidy, and H. Kroop. 1974. The mechanism of action of fosfomycin (phosphenomycin). Ann. N. Y. Acad. Sci. 235:364-386.
25. Kofler, J. W. 1986. Studies of the penetrating ability of fosfomycin into the aqueous humor and vitreous body of the eye. Klin. Monatsbl. Augenheilkd. 18:240-242.
26. Krause, R., S. Patruta, F. Daxböck, P. Fladered, and C. Wenisch. 2001. The effect of fosfomycin on neutrophil function. J. Antimi-crob. Chemother. 47:141-146.
27. Legat, F. J. 2003. Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome. Anti-microb. Agents Chemother. 47:371-374.
28. Marks, H. 1981. Role of water in regulating feed intake and feed efficiency of broilers. Poult. Sci. 60:698-707.
29. Matsumoto, T., K. Tateda, S. Miyazaky, N. Furuya, A. Ohno, Y. Ishii, Y. Hirakata, and K. Yamaguchi. 1997. Immunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomona aeruginosa in mice. Antimicrob. Agents Chemother. 41:308- 313.
30. McKellar, Q. A., S. F. Bruni, and D. G. Jones. 2004. Pharmacokietic/pharmacodinamic relationships of antimicrobial drugs used in veterinary medicine. J. Vet. Pharmacol. Ther. 27:503-514.
31. Michel, C. V., F. Delisle, C. Lependoven, and F. Mignon. 1989. Treatment of peritonitis in continuous ambulatory peritoneal dialysis with a combination of fosfomycin and pefloxacin. Pathol. Biol. (Paris) 37:269-271.
32. Mirakhur, A. 2003. Fosfomycin therapy for multiresistant Pseudomo-nas aeruginosa in cystic fibrosis. J. Cyst. Fibros. 2:19-24.
33. Panetta, J. C., M. Wilkinson, C.-H. Pui, and M. V. Relling. 2002. Limited and optimal sampling strategies for etoposide and etopo-side catechol in children with leukemia. J. Pharmacokinet. Phar-macodyn. 29:171-188.
34. Pfausler, B., H. Spiss, P. Dittrich, M. Zeitlinger, E. Schmutzhard, and C. Joukhadar. 2004. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventric-ulostomy-associated ventriculitis. J. Antimicrob. Chemother. 53:848-852.
35. Quintana, J. A. L. 1988. Manejo de la parvada. Pages 34-48 in Avitecnia: Manejo de las aves domesticas más comunes. Trillas, Mexico City, Mexico.
36. Sauermann, R., R. Karch, H. Langenberger, J. Kettenbach, B. Mayer-Helm, and P. Petsch. 2006. Performance standards for antimicrobial susceptibility testing, sixteenth informational supplement. Approved standard. MS100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
37. Schito, G. 2003. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int. J. Antimicrob. Agents 22:79-83.
38. Singhvi, S. M., A. F. Heald, H. H. Gadebusch, M. E. Resnick, L. T. Difazio, and M. A. Leitz. 1977. Human serum protein binding of cephalosporin antibiotics in vitro. J. Lab. Clin. Med. 89:414-420.
39. Stengel, D. 2005. Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin. J. Chemother. 17:527-535.
40. Stricker, T., S. Fröhlich, and D. Nadal. 1998. Osteomyelitis and septic arthritis due to Citrobacter freundii and Haemophilus influenzae type b. J. Paediatr. Child Health 34:90-91.
41. Sumano, H., L. Ocampo, and L. Gutierrez. 2007. Intravenous and intramuscular pharmacokinetics of a single-daily dose of disodium-fosfomycin in cattle, administered for 3 days. J. Vet. Pharmacol. Ther. 30:49-54.
42. Vermeulen, B., P. Backer, and J. P. De Remon. 2002. Drug administration to poultry. Adv. Drug Deliv. Rev. 54:795-803.
43. Zozaya, H., L. Ocampo, L. Gutiérrez, and H. Sumano. 2008. Phar-macokinetics of a single bolus intravenous, intramuscular and subcutaneous dose of disodium fosfomycin in horses. J. Vet. Pharmacol. Ther. 31:321-327.